{"id":14760,"date":"2011-04-01T13:10:08","date_gmt":"2011-04-01T13:10:08","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=14760"},"modified":"2011-04-01T13:10:08","modified_gmt":"2011-04-01T13:10:08","slug":"no-interaction-between-raltegravir-and-oral-contraceptives","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/14760","title":{"rendered":"No interaction between raltegravir and oral contraceptives"},"content":{"rendered":"<p><strong>HIV-druginteractions.org<\/strong><\/p>\n<p>A placebo-controlled, randomised, two-period crossover study in 19 healthy HIV-seronegative women was conducted to assess the effect of raltegravir (400 mg twice daily) on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and norgestimate.<\/p>\n<p>The geometric mean ratio (GMR) and 90% confidence interval (CI) for ethinylestradiol when co-administrated with raltegravir relative to alone was 0.98 (0.93\u00961.04) for AUC and 1.06 (0.98\u00961.14) for Cmax.  The GMR (90% CI) for norelgestromin (an active metabolite of norgestimate) when co-administered with raltegravir relative to alone was 1.14 (1.08\u00961.21) for AUC and 1.29 (1.23\u00961.37) for Cmax. There were no discontinuations due to a study drug-related adverse experience, nor any serious clinical or laboratory adverse experience.<\/p>\n<p>Raltegravir had no clinically important effect on ethinylestradiol or norgestimate pharmacokinetics and no dose adjustment is required for oral contraceptives containing this combination when co-administered with raltegravir.<\/p>\n<p>Source:<\/p>\n<p><a href=\"http:\/\/www.HIV-druginteractions.org\">www.HIV-druginteractions.org<\/a> (24 March 2011).<\/p>\n<p>Reference:<\/p>\n<p>Anderson MS et al. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.  Br J Clin Pharmacol, 2011, 71(4): 616-620.<br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21395656\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21395656<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIV-druginteractions.org A placebo-controlled, randomised, two-period crossover study in 19 healthy HIV-seronegative women was conducted to assess the effect of raltegravir (400 mg twice daily) on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and norgestimate. The geometric mean ratio (GMR) &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-14760","post","type-post","status-publish","format-standard","hentry","category-pk-and-drug-interactions"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=14760"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14760\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=14760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=14760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=14760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}